Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

BACKGROUND: Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma with one or more prior lines of therapy. CASE PRESE...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Exp Hematol Oncol
Hlavní autoři: Usmani, Saad Z., Khan, Imran, Chiu, Christopher, Foureau, David, Druhan, Lawrence J., Rigby, Katherine, Casneuf, Tineke, Sasser, A. Kate
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5804097/
https://ncbi.nlm.nih.gov/pubmed/29445583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0096-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky